Newbury Pharmaceuticals AB (NEWBRY) — Tangible Net Worth Ratio
Newbury Pharmaceuticals AB (NEWBRY) has a Tangible Net Worth Ratio of 100.0% as of February 2026. This metric is calculated by deducting intangible assets (Skr0.00) from net assets (Skr31.30 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore NEWBRY shareholders equity momentum to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Newbury Pharmaceuticals AB Tangible Net Worth Ratio (2021–2024)
This chart shows how Newbury Pharmaceuticals AB's Tangible Net Worth Ratio has changed across 4 annual periods from 2021 to 2024. As of February 2026, the ratio stands at 100.0%, reflecting net assets of Skr31.30 Million with intangible assets of Skr0.00 SEK. For live market cap and overall valuation, see market value of Newbury Pharmaceuticals AB.
Annual Tangible Net Worth Ratio for Newbury Pharmaceuticals AB (2021–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Newbury Pharmaceuticals AB from 2021 to 2024, covering 4 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. See cash generation quality of Newbury Pharmaceuticals AB to measure how efficiently the company converts operating cash flow to free cash.
| Year | Tangible NW Ratio | Net Assets (SEK) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 12.1% | Skr51.92 Million | Skr45.64 Million | Skr90.87 Million | ▲ +0.3 pp |
| 2023 | 11.8% | Skr49.38 Million | Skr43.55 Million | Skr72.92 Million | ▼ -19.3 pp |
| 2022 | 31.1% | Skr68.77 Million | Skr47.39 Million | Skr86.91 Million | ▼ -8.9 pp |
| 2021 | 40.0% | Skr38.47 Million | Skr23.09 Million | Skr42.81 Million | — |